サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：経肺ドラッグデリバリーシステム市場：2021年～2026年の予測
市場調査レポート
商品コード
1032894

経肺ドラッグデリバリーシステム市場：2021年～2026年の予測

Pulmonary Drug Delivery Systems Market - Forecasts from 2021 to 2026
出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日
AI翻訳ツール 提供対象
ご購入後の翻訳ツール提供について

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
経肺ドラッグデリバリーシステム市場：2021年～2026年の予測
出版日: 2021年08月17日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

経肺ドラッグデリバリーシステムの市場規模は、2019年に409億2900万米ドルとなりました。同市場は、今後4.83%のCAGRで拡大し、2026年には569億4200万米ドルに達すると予測されています。世界的に慢性呼吸器疾患の罹患率が高まっていることが、予測期間中の経肺ドラッグデリバリーシステム市場の成長を牽引します。世界保健機関によると、10億人以上の人々が急性または慢性の呼吸器疾患に苦しんでいます。また、約400万人が慢性呼吸器疾患により早死にしています。また、世界では約2億3,500万人が喘息を患っており、喘息による死亡の80%以上が低・中所得国で発生しています。このような疾患の発生率が高まると、治療のために経肺ドラッグデリバリーシステムを必要とする患者が増加するため、市場の成長が見込まれます。

当レポートでは、経肺ドラッグデリバリーシステム市場について調査し、市場の概要とともに、製品別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 仮定

第3章 エグゼクティブサマリー

  • 調査のハイライト

第4章 市場力学

  • 市場の促進要因
  • 市場の抑制要因
  • ポーターのファイブフォース分析
    • 売り手の交渉力
    • 買い手の交渉力
    • 新規参入企業の脅威
    • 代替品の脅威
    • 機能における競合企業との関係
  • 業界のバリューチェーン分析

第5章 経肺ドラッグデリバリーシステム市場分析、製品別

  • イントロダクション
  • 定量吸入器（MDI）
  • ドライパウダー吸入器（DPI）
  • ソフトミスト吸入器（SMI）
  • ネブライザー

第6章 経肺ドラッグデリバリーシステム市場分析、流通チャネル別

  • イントロダクション
  • オフライン
  • オンライン

第7章 経肺ドラッグデリバリーシステム市場分析、地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • 中東・アフリカ
    • サウジアラビア
    • イスラエル
    • その他
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • インドネシア
    • 台湾
    • タイ
    • その他

第8章 競合情報

  • 競合ベンチマーキングと分析
  • 最近の投資と取引
  • キープレーヤーの戦略

第9章 企業プロファイル

  • Philips Respironics
  • GlaxoSmithKline PLC
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceutical Industries Ltd.
  • 3M Healthcare
  • PARI GmbH
  • F. Hoffmann-La Roche AG
  • Gilbert Technologies
  • AstraZeneca PLC
目次
Product Code: KSI061611953

The pulmonary drug delivery systems market is projected to grow at a CAGR of 4.83% to reach US$56.942 billion by 2026, from US$40.929 billion in 2019. The increasing prevalence of the chronic respiratory disease worldwide will drive the market growth of the pulmonary drug delivery systems market during the forecast period. According to the World Health Organization, more than 1 billion people suffer from either acute or chronic respiratory conditions. Around 4 million people die prematurely from chronic respiratory diseases. In addition, nearly 235 million people suffer from asthma in the world and over 80% of the deaths due to Asthma occur in low and middle-income countries. The increasing incidence of such diseases will support the market growth as more patients will require the pulmonary drug delivery system for their treatment.

Increasing geriatric population

Moreover, the rapidly growing geriatric population worldwide will contribute to the market growth as they are more prone to chronic respiratory diseases such as bronchitis, tuberculosis, and chronic obstructive pulmonary disease, etc. which will surge the demand for pulmonary drug delivery systems in the market. According to the United Nations, in 2019, the geriatric population was 703 million persons, nationwide. The number of older persons is projected to double to 1.5 billion in 2050.

Health awareness

Furthermore, the growing health awareness and increasing investment in the healthcare and drug delivery industry by both public and private players are also expected to further fuel up the growth of the market. Also, the initiative taken by the governing bodies of various countries is increasing health awareness among the people. For instance, the National Asthma Control Program (NACP) by CDS, provides funds for educating asthma-affected patients. Such initiatives will encourage more patients to adopt pulmonary drug delivery systems for their treatment which will further strengthen the market growth during the forecast period.

Market Segmentation

By product, the dry powder inhalers (DPIs) segment is projected to hold a significant market share owing to the advantages such as short administration & preparation time, ease of use, and fewer irritant effects associated with the use of these inhalers. Geographically, North America holds a significant market share due to the increasing prevalence of chronic respiratory diseases, early adoption of the pulmonary drug delivery systems, and the surge in healthcare spending in the region. Asia Pacific will be the fastest-growing market region owing to the rapidly growing geriatric population, increasing adoption of an unhealthy lifestyle, and rising urbanization in the region.

Growth Factors

Increase in the geriatric population

The increase in the geriatric population across the globe is expected to drive the market growth of pulmonary drug delivery systems. According to COPD, about 1 in 7 older adults suffers from some of the other forms of lung disease. The geriatric population is more prone to chronic respiratory diseases as compared to the younger population which will increase the demand for pulmonary drug delivery systems in the market during the forecast period.

Restraints

Lack of awareness

The pulmonary drug delivery system is a relatively new system due to which not many patients are aware of the advantages of using this system which may restrain the market growth during the forecast period. The patients, especially in the developing countries are unaware of the existence of this system due to which the demand for it is low in these countries. However, with the increasing awareness by both the public and private players the patients are expected to become aware and adopt these systems.

Impact of COVID-19 on the pulmonary drug delivery systems market

The Covid-19 pandemic positively impacted the pulmonary drug delivery systems market as the novel coronavirus directly or indirectly attacks the respiratory system of the patient. There was a rapid spike in the number of patients suffering from respiratory diseases as the potent virus made their lungs weak, which, in turn, increased the demand for pulmonary drug delivery systems, worldwide. The virus outbreak continues to linger in many countries even after a year which is expected to further drive the market growth during the forecast period.

Competitive Insights

The market leaders for the pulmonary drug delivery systems market consist of Philips Respironics, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., 3M Healthcare, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, and AstraZeneca PLC. The key players in the market implement growth strategies such as product launches, mergers, and acquisitions, etc. to gain a competitive advantage over their competitors.

Segmentation

By Product

  • Metered-dose inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • Soft mist inhaler (SMI)
  • Nebulizers

By Distribution Channel

  • Offline
  • Online

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Indonesia
    • Taiwan
    • Thailand
    • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Pulmonary Drug Delivery Systems Market Analysis, By Product

  • 5.1. Introduction
  • 5.2. Metered-dose inhalers (MDIs)
  • 5.3. Dry Powder Inhalers (DPIs)
  • 5.4. Soft mist inhaler (SMI)
  • 5.5. Nebulizers

6. Pulmonary Drug Delivery Systems Market Analysis, By Distribution Channel

  • 6.1. Introduction
  • 6.2. Offline
  • 6.3. Online

7. Pulmonary Drug Delivery Systems Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
    • 7.2.4. Others
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Indonesia
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Others

8. Competitive Intelligence

  • 8.1. Competitive Benchmarking and Analysis
  • 8.2. Recent Investment and Deals
  • 8.3. Strategies of Key Players

9. Company Profiles

  • 9.1. Philips Respironics
  • 9.2. GlaxoSmithKline PLC
  • 9.3. Boehringer Ingelheim GmbH
  • 9.4. Teva Pharmaceutical Industries Ltd.
  • 9.5. 3M Healthcare
  • 9.6. PARI GmbH
  • 9.7. F. Hoffmann-La Roche AG
  • 9.8. Gilbert Technologies
  • 9.9. AstraZeneca PLC